CMO of Youngene Therapeutics will give a speech at the 2022EASD European Annual ...
News Express | The Latest Analysis of Double SGLT InhibitorsPhase lll Trial Rele...
lntestinal SGLT1 as a therapeutic target in COVID-19-relateddiabetes: A "two-edg...
Sotagliflozin, a SGLT1/SGLT2 dual inhibitor submitted listingapplication to FDA ...
Youngene Therapeutics ls Invited To Attend EASD This Year
First Patient Enrolled - YG1699 Type 1 Diabetes Phase llClinical Study in the Un...
Phase ll Clinical Trial Of YG1699 For Type l Diabetes Has BeenCarried Out In The...
Primary Endpoint Successfully Met in Phase 2 Study of YG1699
Youngene Therapeutics Announced: An lmportant MedicalLeaders On Board